Clinical trials: Radiation Dose Reduction, open to volunteers
Basal Ganglia Germinoma, Diabetes Insipidus
A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma
This phase II trial studies how well lower dose radiotherapy after chemotherapy (Carboplatin \& Etoposide) works in treating children with central nervous system (CNS) germinomas.
- Conditions
- Basal Ganglia Germinoma, Diabetes Insipidus, Germinoma, Pineal Region Germinoma
- Trial name
- NCT06368817
- Testing
- 3-Dimensional Conformal Proton Radiation Therapy, 3-Dimensional Conformal Radiation Therapy, Biospecimen Collection
- Where
- 115 sites in United States, Australia and 1 more
- Volunteers
- 240 people
- Sponsor
- Children's Oncology Group
Radiation Dose Reduction
Multicenter Pediatric Low-Dose CT Protocol: Development and Clinical Verification
Children are sensitive to ionizing radiation, and there are significant regional variations in current pediatric CT radiation doses.
- Trial name
- NCT07199101
- Testing
- Low dose CT
- Where
- 20 sites in China
- Volunteers
- 2,650 people
- Sponsor
- Beijing Children's Hospital
Refractory Leukemia
Chemotherapy CLAGE-Ven Sequential With Reduced Intensity Conditioning for Refractory Acute Myelodi Leukemia
The investigators developed a protocol combining chemotherapy of cladribine, cytarabine and etoposide (CLAGE) as debulking treatment sequential with reduced intensity conditioning regimen Flu-Bu to treat patients with refractory…
- Trial name
- NCT05870995
- Testing
- CALGE-VEN- RIC-conditioning
- Where
- 3 sites in China
- Volunteers
- 100 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Pediatric Hodgkin's Disease
Pediatric Hodgkin Lymphoma Treatment Trial With Low Cumulative Doses of Chemotherapy Agents and Reduced Radiation.
This trial proposes a therapy for pediatric Hodgkin lymphoma with the objective of achieving high levels of long lasting complete remission with less risk of late effects.
- Trial name
- LHGALOP2017 (NCT03500133)
- Testing
- No radiotherapy if CR at the end of chemotherapy., Low risk with complete early response after two cycles of ABVD chemotherapy schedule. Only one more ABVD course is delivered., Low risk with partial remisssion after 4 cycles of ABVD chemotherapy schedule. Two ESHAP courses are delivered.
- Where
- Argentina
- Volunteers
- 500 people
- Sponsor
- Hospital JP Garrahan